Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans

被引:42
作者
Green, A. R. [1 ]
King, M. V. [1 ]
Shortall, S. E. [1 ]
Fone, K. C. F. [1 ]
机构
[1] Univ Nottingham, Sch Biomed Sci, Queens Med Ctr, Nottingham NG7 2UH, England
关键词
3; 4-methylenedioxymethamphetamine; MDMA; ecstasy; pharmacokinetics; pharmacodynamics; quantitative pharmacology; 5-hydroxytryptamine; neurotoxicity; hyperthermia; CORE BODY-TEMPERATURE; LONG-TERM CHANGES; MDMA ECSTASY; SEROTONIN NEUROTOXICITY; CAVEAT-EMPTOR; HYPERTHERMIC RESPONSE; ALPHA-METHYLDOPAMINE; AMBIENT-TEMPERATURE; BRAIN; RATS;
D O I
10.1111/j.1476-5381.2011.01819.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
3,4-Methylenedioxymethamphetamine (MDMA) induces both acute adverse effects and long-term neurotoxic loss of brain 5-HT neurones in laboratory animals. However, when choosing doses, most preclinical studies have paid little attention to the pharmacokinetics of the drug in humans or animals. The recreational use of MDMA and current clinical investigations of the drug for therapeutic purposes demand better translational pharmacology to allow accurate risk assessment of its ability to induce adverse events. Recent pharmacokinetic studies on MDMA in animals and humans are reviewed and indicate that the risks following MDMA ingestion should be re-evaluated. Acute behavioural and body temperature changes result from rapid MDMA-induced monoamine release, whereas long-term neurotoxicity is primarily caused by metabolites of the drug. Therefore acute physiological changes in humans are fairly accurately mimicked in animals by appropriate dosing, although allometric dosing calculations have little value. Long-term changes require MDMA to be metabolized in a similar manner in experimental animals and humans. However, the rate of metabolism of MDMA and its major metabolites is slower in humans than rats or monkeys, potentially allowing endogenous neuroprotective mechanisms to function in a species specific manner. Furthermore acute hyperthermia in humans probably limits the chance of recreational users ingesting sufficient MDMA to produce neurotoxicity, unlike in the rat. MDMA also inhibits the major enzyme responsible for its metabolism in humans thereby also assisting in preventing neurotoxicity. These observations question whether MDMA alone produces long-term 5-HT neurotoxicity in human brain, although when taken in combination with other recreational drugs it may induce neurotoxicity. LINKED ARTICLES This article is commented on by Parrott, pp. 15181520 of this issue. To view this commentary visit and to view the the rebuttal by the authors (Green et al., pp. 15211522 of this issue) visit
引用
收藏
页码:1523 / 1536
页数:14
相关论文
共 121 条
  • [1] [Anonymous], 2010, ISR STAT COMPTR REP
  • [2] Serotonergic neurotoxicity of 3,4-(±) -methylenedioxyamphetamine and 3,4-(±)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of γ-glutamyl transpeptidase
    Bai, FJ
    Jones, DC
    Lau, SS
    Monks, TJ
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2001, 14 (07) : 863 - 870
  • [3] Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity:: Possible role in methylenedioxyamphetamine-mediated neurotoxicity
    Bai, FJ
    Lau, SS
    Monks, TJ
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 1999, 12 (12) : 1150 - 1157
  • [4] NEURAL AND CARDIAC TOXICITIES ASSOCIATED WITH 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA)
    Baumann, Michael H.
    Rothman, Richard B.
    [J]. NEW CONCEPTS OF PSYCHOSTIMULANTS INDUCED NEUROTOXICITY, 2009, 88 : 257 - 296
  • [5] Effects of Dose and Route of Administration on Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine in the Rat
    Baumann, Michael H.
    Zolkowska, Dorota
    Kim, Insook
    Scheidweiler, Karl B.
    Rothman, Richard B.
    Huestis, Marilyn A.
    [J]. DRUG METABOLISM AND DISPOSITION, 2009, 37 (11) : 2163 - 2170
  • [6] Boxenbaum H, 1990, Adv Drug Res, V19, P139
  • [7] L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions
    Breier, JM
    Bankson, MG
    Yamamoto, BK
    [J]. JOURNAL OF NEUROSCIENCE, 2006, 26 (01) : 290 - 299
  • [8] Instability of the ecstasy market and a new kid on the block: mephedrone
    Brunt, Tibor M.
    Poortman, Anneke
    Niesink, Raymond J. M.
    van den Brink, Wim
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2011, 25 (11) : 1543 - 1547
  • [9] Pre-treatment with 3,4-methylenedioxymethamphetamine (MDMA) causes long-lasting changes in 5-HT2A receptor-mediated glucose utilization in the rat brain
    Bull, EJ
    Porkess, V
    Rigby, M
    Hutson, PH
    Fone, KCF
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2006, 20 (02) : 272 - 280
  • [10] Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT2A receptor responsivity
    Bull, EJ
    Hutson, PH
    Fone, KCF
    [J]. NEUROPHARMACOLOGY, 2004, 46 (02) : 202 - 210